NCT05658913

Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 100 (estimated)
• Sponsor: University of Pennsylvania · Academic / Other
• Sex: All
• Age: 18 Years – 120 Years
• Healthy volunteers: Not accepted

Summary

To collect Tau PET/CT imaging in older adults diagnosed with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) in the Mismatch Prospective Cohort Study (MPC-Tau) study to determine relationship to clinical, cognitive, and other biomarker data. Findings from this study will likely provide insight into the phenotypic variability of Alzheimer's Disease and other related pathologies.

Detailed description

This is a cross-sectional study using the radiotracer AV-1451 to determine the relationship of tau pathology to other biomarker data of MPC participants. All subjects will already have been enrolled in the MPC Study. For the current protocol, participants will provide informed consent before beginning any study procedures. After screening assessments, participants will undergo PET/CT scan imaging with AV-1451.

Conditions

• Alzheimer's Disease

Interventions

Type	Name	Description
DRUG	AV-1451	This is a cross-sectional study using the radiotracer AV-1451 to determine the relationship of tau pathology to other biomarker data of MPC participants.

Timeline

• Start date: 2023-03-14
• Primary completion: 2027-12-01
• Completion: 2029-12-01
• First posted: 2022-12-21
• Last updated: 2025-09-05

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study